AAPL308.06+13.68 (+4.65%) ▲|ABBV260.28+9.22 (+3.67%) ▲|ABT95.23+3.05 (+3.31%) ▲|ACN137.34+6.21 (+4.74%) ▲|ADBE219.67+8.69 (+4.12%) ▲|AMAT596.44-54.48 (-8.37%) ▼|AMD513.02-27.87 (-5.15%) ▼|AMGN373.03+11.70 (+3.24%) ▲|AMT165.72-0.36 (-0.22%) ▼|AMZN243.42+1.72 (+0.71%) ▲|AVGO360.59-8.76 (-2.37%) ▼|AXP351.20+4.15 (+1.20%) ▲|BA225.98+7.40 (+3.38%) ▲|BAC58.62+0.26 (+0.45%) ▲|BKNG184.56+1.92 (+1.05%) ▲|BLK992.05+11.67 (+1.19%) ▲|BMY57.97+2.16 (+3.87%) ▲|BNY146.19+0.17 (+0.12%) ▲|BRK-B506.38+6.64 (+1.33%) ▲|C139.65-0.48 (-0.34%) ▼|CAT963.39-28.02 (-2.83%) ▼|CL95.20+2.44 (+2.63%) ▲|CMCSA23.75+0.02 (+0.06%) ▲|COF204.38-0.44 (-0.21%) ▼|COP104.26+1.04 (+1.01%) ▲|COST951.40+26.73 (+2.89%) ▲|CRM165.36+2.13 (+1.30%) ▲|CSCO112.72-4.29 (-3.67%) ▼|CVS104.70-0.12 (-0.11%) ▼|CVX168.74+3.05 (+1.84%) ▲|DE620.75-6.88 (-1.10%) ▼|DHR197.24+3.52 (+1.82%) ▲|DIS99.28+3.57 (+3.73%) ▲|DUK129.46+3.69 (+2.93%) ▲|EMR138.93-0.60 (-0.43%) ▼|FDX313.07-0.82 (-0.26%) ▼|GD372.16+10.89 (+3.01%) ▲|GE376.93+1.99 (+0.53%) ▲|GEV1,109.39-24.96 (-2.20%) ▼|GILD131.18+5.21 (+4.14%) ▲|GM75.74+0.22 (+0.29%) ▲|GOOG356.40-1.49 (-0.42%) ▼|GOOGL360.23-0.98 (-0.27%) ▼|GS1,020.83+1.22 (+0.12%) ▲|HD357.29+6.45 (+1.84%) ▲|HON229.59+7.84 (+3.54%) ▲|IBM288.58+2.33 (+0.81%) ▲|INTC119.07-7.95 (-6.26%) ▼|INTU274.74+7.66 (+2.87%) ▲|ISRG425.32+22.94 (+5.70%) ▲|JNJ261.96+7.98 (+3.14%) ▲|JPM333.40-0.68 (-0.20%) ▼|KO83.75+2.46 (+3.02%) ▲|LIN545.51+11.96 (+2.24%) ▲|LLY1,203.65+11.91 (+1.00%) ▲|LMT544.69+22.87 (+4.38%) ▲|LOW226.79+4.87 (+2.19%) ▲|LRCX348.45-42.82 (-10.94%) ▼|MA538.21+15.77 (+3.02%) ▲|MCD280.20+10.77 (+4.00%) ▲|MDLZ60.92+1.57 (+2.65%) ▲|MDT83.16+3.96 (+5.00%) ▲|META584.25-28.66 (-4.68%) ▼|MMM160.71+0.75 (+0.47%) ▲|MO72.64+1.10 (+1.54%) ▲|MRK128.98+3.61 (+2.88%) ▲|MS214.00+2.14 (+1.01%) ▲|MSFT390.56+6.28 (+1.63%) ▲|MU963.56-68.72 (-6.66%) ▼|NEE88.14+1.77 (+2.05%) ▲|NFLX77.79+3.60 (+4.85%) ▲|NKE44.05+0.99 (+2.30%) ▲|NOW105.65-0.15 (-0.14%) ▼|NVDA194.53-3.05 (-1.54%) ▼|ORCL140.17-2.34 (-1.64%) ▼|PEP144.21+3.05 (+2.16%) ▲|PFE24.31+0.43 (+1.78%) ▲|PG150.88+3.45 (+2.34%) ▲|PLTR129.85+4.12 (+3.28%) ▲|PM182.64+4.95 (+2.79%) ▲|QCOM175.15-6.77 (-3.72%) ▼|RTX199.15+7.37 (+3.84%) ▲|SBUX104.31+0.92 (+0.89%) ▲|SCHW96.96+1.18 (+1.23%) ▲|SO97.81+2.69 (+2.83%) ▲|SPG225.49+2.49 (+1.11%) ▲|T20.55+0.07 (+0.34%) ▲|TMO520.99+7.66 (+1.49%) ▲|TMUS177.55+4.49 (+2.59%) ▲|TSLA392.94-32.36 (-7.61%) ▼|TXN291.69-6.72 (-2.25%) ▼|UBER74.40+1.74 (+2.39%) ▲|UNH423.95-2.60 (-0.61%) ▼|UNP281.85+4.12 (+1.48%) ▲|UPS110.39+0.85 (+0.78%) ▲|USB61.56-0.40 (-0.65%) ▼|V360.35+9.27 (+2.64%) ▲|VZ42.56+0.57 (+1.36%) ▲|WFC85.49-0.45 (-0.52%) ▼|WMT112.01+3.19 (+2.93%) ▲|XOM136.75+0.47 (+0.34%) ▲|AAPL308.06+13.68 (+4.65%) ▲|ABBV260.28+9.22 (+3.67%) ▲|ABT95.23+3.05 (+3.31%) ▲|ACN137.34+6.21 (+4.74%) ▲|ADBE219.67+8.69 (+4.12%) ▲|AMAT596.44-54.48 (-8.37%) ▼|AMD513.02-27.87 (-5.15%) ▼|AMGN373.03+11.70 (+3.24%) ▲|AMT165.72-0.36 (-0.22%) ▼|AMZN243.42+1.72 (+0.71%) ▲|AVGO360.59-8.76 (-2.37%) ▼|AXP351.20+4.15 (+1.20%) ▲|BA225.98+7.40 (+3.38%) ▲|BAC58.62+0.26 (+0.45%) ▲|BKNG184.56+1.92 (+1.05%) ▲|BLK992.05+11.67 (+1.19%) ▲|BMY57.97+2.16 (+3.87%) ▲|BNY146.19+0.17 (+0.12%) ▲|BRK-B506.38+6.64 (+1.33%) ▲|C139.65-0.48 (-0.34%) ▼|CAT963.39-28.02 (-2.83%) ▼|CL95.20+2.44 (+2.63%) ▲|CMCSA23.75+0.02 (+0.06%) ▲|COF204.38-0.44 (-0.21%) ▼|COP104.26+1.04 (+1.01%) ▲|COST951.40+26.73 (+2.89%) ▲|CRM165.36+2.13 (+1.30%) ▲|CSCO112.72-4.29 (-3.67%) ▼|CVS104.70-0.12 (-0.11%) ▼|CVX168.74+3.05 (+1.84%) ▲|DE620.75-6.88 (-1.10%) ▼|DHR197.24+3.52 (+1.82%) ▲|DIS99.28+3.57 (+3.73%) ▲|DUK129.46+3.69 (+2.93%) ▲|EMR138.93-0.60 (-0.43%) ▼|FDX313.07-0.82 (-0.26%) ▼|GD372.16+10.89 (+3.01%) ▲|GE376.93+1.99 (+0.53%) ▲|GEV1,109.39-24.96 (-2.20%) ▼|GILD131.18+5.21 (+4.14%) ▲|GM75.74+0.22 (+0.29%) ▲|GOOG356.40-1.49 (-0.42%) ▼|GOOGL360.23-0.98 (-0.27%) ▼|GS1,020.83+1.22 (+0.12%) ▲|HD357.29+6.45 (+1.84%) ▲|HON229.59+7.84 (+3.54%) ▲|IBM288.58+2.33 (+0.81%) ▲|INTC119.07-7.95 (-6.26%) ▼|INTU274.74+7.66 (+2.87%) ▲|ISRG425.32+22.94 (+5.70%) ▲|JNJ261.96+7.98 (+3.14%) ▲|JPM333.40-0.68 (-0.20%) ▼|KO83.75+2.46 (+3.02%) ▲|LIN545.51+11.96 (+2.24%) ▲|LLY1,203.65+11.91 (+1.00%) ▲|LMT544.69+22.87 (+4.38%) ▲|LOW226.79+4.87 (+2.19%) ▲|LRCX348.45-42.82 (-10.94%) ▼|MA538.21+15.77 (+3.02%) ▲|MCD280.20+10.77 (+4.00%) ▲|MDLZ60.92+1.57 (+2.65%) ▲|MDT83.16+3.96 (+5.00%) ▲|META584.25-28.66 (-4.68%) ▼|MMM160.71+0.75 (+0.47%) ▲|MO72.64+1.10 (+1.54%) ▲|MRK128.98+3.61 (+2.88%) ▲|MS214.00+2.14 (+1.01%) ▲|MSFT390.56+6.28 (+1.63%) ▲|MU963.56-68.72 (-6.66%) ▼|NEE88.14+1.77 (+2.05%) ▲|NFLX77.79+3.60 (+4.85%) ▲|NKE44.05+0.99 (+2.30%) ▲|NOW105.65-0.15 (-0.14%) ▼|NVDA194.53-3.05 (-1.54%) ▼|ORCL140.17-2.34 (-1.64%) ▼|PEP144.21+3.05 (+2.16%) ▲|PFE24.31+0.43 (+1.78%) ▲|PG150.88+3.45 (+2.34%) ▲|PLTR129.85+4.12 (+3.28%) ▲|PM182.64+4.95 (+2.79%) ▲|QCOM175.15-6.77 (-3.72%) ▼|RTX199.15+7.37 (+3.84%) ▲|SBUX104.31+0.92 (+0.89%) ▲|SCHW96.96+1.18 (+1.23%) ▲|SO97.81+2.69 (+2.83%) ▲|SPG225.49+2.49 (+1.11%) ▲|T20.55+0.07 (+0.34%) ▲|TMO520.99+7.66 (+1.49%) ▲|TMUS177.55+4.49 (+2.59%) ▲|TSLA392.94-32.36 (-7.61%) ▼|TXN291.69-6.72 (-2.25%) ▼|UBER74.40+1.74 (+2.39%) ▲|UNH423.95-2.60 (-0.61%) ▼|UNP281.85+4.12 (+1.48%) ▲|UPS110.39+0.85 (+0.78%) ▲|USB61.56-0.40 (-0.65%) ▼|V360.35+9.27 (+2.64%) ▲|VZ42.56+0.57 (+1.36%) ▲|WFC85.49-0.45 (-0.52%) ▼|WMT112.01+3.19 (+2.93%) ▲|XOM136.75+0.47 (+0.34%) ▲|
38.5 C
New York
Thursday, July 2, 2026

Tag: patients

newssourceFORcompanyinformationcontent1releasesmarket

International Oncology Experts Meet in Kenya to Address Regional Cancer Needs

National Comprehensive Cancer Network and African Cancer Coalition take part in American Cancer Society Global Academy Regional Workshop to improve cancer care in Sub-Saharan...

HepaRegeniX Doses First Patient in Phase Ib Trial with Small Molecule Inhibitor HRX-215 to Promote Liver Regeneration

Tuebingen, Germany, June 10, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver disease, today announced that the first patient has been dosed in their Phase Ib clinical trial of its lead candidate HRX-215. The trial is evaluating the safety and efficacy of HRX-215, an orally available small-molecule inhibitor of MKK4, in patients undergoing partial liver resection due to liver metastases deriving from colorectal cancer. HXR-215 is designed to treat advanced-stage liver disease by increasing the regenerative capacity of hepatocytes. An initial data readout is planned for the second half of 2025.

Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated Cardiomyopathy

LMNA-related dilated cardiomyopathy (LMNA DCM) is one of the most aggressive forms of DCM, affecting approximately 100,000 individuals in the United States and Europe,...

Global Clinical Workflow Management Software Market Projected to Reach USD USD 40,243 million by 2030., Growing at a 22.97% CAGR: MarkNtel Advisors – Leading...

NEW DELHI, June 10, 2025 /PRNewswire/ -- The Global Clinical Workflow Management Software Market size is set to experience significant growth in the coming years....

Caliway to Present First Preclinical Data on CBL-514 for GLP-1 Weight Rebound Management at BIO 2025

Caliway to deliver a corporate presentation on June 17 at the BIO International Convention 2025, the world's largest biotech industry event.For the first time...

Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria

ALY-301 is a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity Designed to enable safe dosing in chronic conditions and deliver clinical proof-of...

Idorsia announces the appointment of Srishti Gupta, MD as CEO to ensure the long-term success of Idorsia

Ad hoc announcement pursuant to Art. 53 LR

Abbisko Therapeutics Announces China NMPA Acceptance of New Drug Application for Pimicotinib for the Treatment of TGCT

SHANGHAI, June 10, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (02256.HK) today announced that the China National Medical Products Administration (NMPA) has accepted the...

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Krispy Kreme, Digimarc, Elevance Health, and Iovance and Encourages...

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Krispy Kreme, Inc. (NASDAQ:DNUT), Digimarc Corporation (NASDAQ:DMRC), Elevance Health, Inc. (NYSE:ELV), and Iovance Biotherapeutics, Inc. (NASDAQ:IOVA). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Linical Celebrates 20 Years of Advancing Clinical Research and Patient Wellbeing

OSAKA, Japan, June 10, 2025 /PRNewswire/ -- Linical, a leader in clinical research services, is proud to celebrate its 20th anniversary — a milestone...

New Survey Finds Younger Adults, More Women Seeking Treatment for Hair Loss

Manageable number of monthly hair restoration surgeries illustrates ISHRS members' hands-on, expert approach CHICAGO, June 10, 2025 /PRNewswire/ -- According to results of a new member survey...

Akesis Biologics Launches MastGut: A Breakthrough Supplement That Uses DUSP10 Enzyme to Support Gut and Colorectal Health

SINGAPORE, June 10, 2025 /PRNewswire/ -- Akesis Biologics, a biotechnology spin-off from the National University of Singapore (NUS), has officially launched its flagship gut...

World’s First Needle-Free Procedure Targeting Deep Facial Muscles and Skin, EMFACE® by BTL Aesthetics Surpasses 1 Million Global Treatments, Drives Rapid Adoption in Singapore’s...

SINGAPORE, June 10, 2025 /PRNewswire/ -- EMFACE® the groundbreaking non-invasive natural facial lifting treatment developed by BTL Aesthetics (BTL), has surpassed 1 million treatments...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatients

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers